quinta-feira , 27 janeiro 2022
Capa » International News

International News

Queen’s University Belfast enters collaboration and licensing agreement with Ipsen to progress FLIP inhibitor project which has been supported by Domainex

Saffron Walden, 26th January 2022 / Sciad Newswire / Domainex Ltd., a leading provider of integrated drug discovery services to life science organisations globally, is delighted that Professors Daniel Longley, Tim Harrison and colleagues at Queen’s University Belfast have entered into a collaboration and licensing agreement with Ipsen. The agreement provides an exclusive licence to research, develop, manufacture and commercialise FLIP inhibitors. Domainex has supported the FLIP inhibitor programme from its inception. Leia Mais »

US sickle cell disease market to skyrocket to $4.8bn by 2030, driven by gene therapies and new first-in-class products, says GlobalData

A number of exciting new sickle cell disease (SCD) drugs are set to hit the US market, says GlobalData, including gene therapies that could offer patients a cure. The leading data and analytics company notes that one of the gene therapies that is currently closest to entering the market— bluebird bio’s bb1111—is projected to represent over a quarter of total sales within the space by 2030. Meanwhile, Droxia, a drug that once was the only approved drug for 20 years, will be drowned out by the newcomers. Leia Mais »

Clasado Biosciences announces new HCP learning event for March 2022

Clasado Biosciences (‘Clasado’), a global leader in the development of clinically proven prebiotic ingredient and product solutions for the human gut microbiome, has revealed details of a new learning event for healthcare professionals.  Leia Mais »

US sees 18.3% increase of drug price per year, according to GlobalData

The average price of branded drugs in the US has increased by a whopping 18.3%* per year, according to research by GlobalData. As patients are hit by yet another price hike in 2022—434 branded drugs in the US saw a price increase on 1 January by an average of 5.2%, according to GoodRx—the leading data and analytics company notes that this trend is the complete opposite to what is occurring in other major pharmaceutical markets worldwide. Leia Mais »

Pediatric eosinophilic esophagitis needs more treatment options in US, finds GlobalData

Limited treatment options for pediatric patients in the US remain a significant unmet need in the eosinophilic esophagitis (EoE) space, providing an opportunity for developers to expand the current clinical studies to pediatric populations, finds GlobalData, a leading data and analytics company. Leia Mais »

Mario Torchia is the new InSilicoTrials’ Vice President of Sales & Marketing

18 January 2022 InSilicoTrials, a leader in simulation software solutions for healthcare, announced today his appointment. Torchia gained 15 years of experience in the tech industry, working in multinational companies such as Dassault Systèmes and Siemens.

Most recently he led the Sales Strategy as Delmia Geo Leader for South Europe at Dassault Systèmes, actively supporting customers in their business transformation journey. Leia Mais »

Psoriasis development criteria more competitive than ever, says GlobalData

The psoriasis (PsO) market has typically been dominated by injectable biologics. However, this segment has become fairly saturated, given the number of different efficacious biologics already available. As a result, drug manufacturers now have no choice but to continue setting and exceeding increasingly high clinical development standards to gain a foothold in this mature field, as noted by key opinion leaders (KOLs) interviewed by GlobalData, a leading data and analytics company. Leia Mais »

Restrictive Medicare coverage spells continued uncertainty for Aduhelm, says GlobalData

Following the Centers for Medicare & Medicaid Services’ (CMS) announcement of draft guidance on its highly anticipated reimbursement decision regarding Aduhelm (aducanumab) and other future anti-amyloid monoclonal antibody (mAb) products in Alzheimer’s disease (AD); Leia Mais »

Duchenne muscular dystrophy drug pipeline variation is promising, says GlobalData

By 2030, patients living with Duchenne muscular dystrophy (DMD) — a genetic muscle wasting disease caused by mutations on the gene that produces dystrophin — will have greater choice when it comes to the drug types used for treatment, according to GlobalData. The leading data and analytics company notes that there are 23 DMD-targeting therapeutics currently being developed in the US and Japan, and eight of these have the potential to make it to market in the next 10 years. Leia Mais »

Datwyler makes its debut at fce pharma with high-quality, system-critical components for vaccine providers

Middletown, DE, December 1, 2021 – At FCE Pharma (November 30 – December 2, 2021; São Paulo) Datwyler, (Booth G098) will highlight its high-quality, system-critical elastomer components for injectable drugs such as the COVID-19 vaccine. Since the start of the pandemic, Datwyler has supplied system-critical components including stoppers and aluminum seals to vaccine developers around the world. Leia Mais »

Fale com os gestores